Nebulisable liposomes – Method for the pulmonary delivery of agents
The treatment of lung and respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD), pneumonia and pulmonary hypertension, is carried out by means of agents with a long biological half-life. Liposomes are favoured that remain as stable as possible during nebulisation and that achieve a delayed release of the agent with as few side-effects as possible.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…
ASXL1 Mutation: The Hidden Trigger Behind Blood Cancers and Inflammation
Scientists show how a mutated gene harms red and white blood cells. LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have discovered how a mutated gene kicks off…